Clinical trial · Observational
Muscle Parameters and Pathological Response in Breast Cancer Patients
The Relation Between the Initial Value of the Skeletal Mass Index and Pathological Response
NCT06151379CI-TRIAL-00071857completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators aimed to accurately measure muscle mass and predict pCR to NAC and its effect on clinical outcomes.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neoadjuvant Chemotherapy | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Neoadjuvant therapy | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Pathologic complete response (pCR)
- description
- Patient with complete pathological response
- interventionNames
- Other: Neoadjuvant therapy
- label
- Pathologic incomplete response (non-pCR)
- description
- Patient with partial pathological response
- interventionNames
- Other: Neoadjuvant therapy
Primary outcomes (1)
- measure
- Sarcopenic index
- timeFrame
- Through study completion, an average of 1 year.
- description
- skeletal muscle area (cm2)/height (m2) et L3 level
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 29 Years
- Maximum age
- 72 Years
Show eligibility criteria text
Inclusion Criteria: * Early and locally advanced operated breast cancer patients receiving neoadjuvant chemotherapy. Exclusion Criteria: * Patients who did not receive neoadjuvant chemotherapy, had metastatic breast cancer and whose radiological images were not available.
References
Publications (0)
Data not yet available
No reference posted for this study.